<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879398</url>
  </required_header>
  <id_info>
    <org_study_id>A0221075</org_study_id>
    <nct_id>NCT00879398</nct_id>
  </id_info>
  <brief_title>Toviaz Post Marketing Surveillance Study</brief_title>
  <official_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of Toviaz (Registered)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the problems and questions of safety and efficacy
      of Toviaz® under the standard conditions of usage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      continuous registration method
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From the time that the participant signed data privacy statement through and including 28 calendar days after the last administration of the study drug.</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event was not necessarily had a causal relationship with the treatment or usage. All AEs reported after start of administration of Toviaz were considered as TEAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Final Assessment of Effectiveness at the End of Study Treatment</measure>
    <time_frame>At the end of study treatment</time_frame>
    <description>The final efficacy assessment included improvement, no change, aggravation, and unevaluable evaluated by the investigator based on the subject's symptoms of frequent micturition, urgency, and urgency urinary incontinence (UUI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Micturitions Per 24 Hours at the End of Study Treatment</measure>
    <time_frame>Baseline and at the end of study treatment</time_frame>
    <description>The number of micturitions per 24 hours was recorded in the case report form (CRF) by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Urgency Episodes Per 24 Hours at the End of Study Treatment</measure>
    <time_frame>Baseline and at the end of study treatment</time_frame>
    <description>The number of urgency episodes per 24 hours was recorded in the CRF by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of UUI Episodes Per 24 Hours at the End of Study Treatment</measure>
    <time_frame>Baseline and at the end of study treatment</time_frame>
    <description>The number of UUI episodes per 24 hours was recorded in the CRF by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Perception of Bladder Condition at the End of Study Treatment</measure>
    <time_frame>Baseline and at the end of study treatment</time_frame>
    <description>Participant perception of bladder condition was recorded in the CRF by the investigator. Participants were asked at baseline (BL) and at the end of study treatment (EOT) if the extent to which their bladder condition caused them problems. The possible responses were: No Problem, Very Minor Problems, Minor Problems, Moderate Problems, Severe Problems, or Many Severe Problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Final Efficacy Assessment of Effective by Baseline and Treatment Characteristics</measure>
    <time_frame>At the end of study treatment</time_frame>
    <description>Participants who were assessed as having improved from their baseline condition in the final efficacy assessment were considered as &quot;effective&quot;. Baseline and treatment characteristics included: geriatric status (&lt;65 years or ≥65 years), age categories, gender, weight categories, height categories, allergic history, duration of disease, past overactive bladder (OAB) treatment history, medical history, kidney and liver disorders, concomitant medication, total administration period of Toviaz, completion status, daily dose of Toviaz, and long term administration of Toviaz (&lt;274 days and ≥274 days) .</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3000</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>OAB-Toviaz</arm_group_label>
    <description>All patients who enrolled in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toviaz treatment</intervention_name>
    <description>4 mg starting then can be followed by 8 mg</description>
    <arm_group_label>OAB-Toviaz</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - Subjects who are diagnosed as Overactive Bladder (OAB) defined as urgency, with or
        without urgency incontinence, usually with frequency and nocturia, in the absence of local
        or metabolic factors explaining these factors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are diagnosed as Overactive Bladder (OAB) defined as urgency, with or
             without urgency incontinence, usually with frequency and nocturia, in the absence of
             local or metabolic factors explaining these factors.

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to peanut or soya or any of the excipients

          -  Urinary retention

          -  Gastric retention

          -  Uncontrolled narrow angle glaucoma

          -  Myasthenia gravis

          -  Severe hepatic impairment (Child Pugh C)

          -  Concomitant use of potent CYP3A4 inhibitors in subjects with moderate to severe
             hepatic or renal impairment

          -  Severe ulcerative colitis

          -  Toxic megacolon

          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption (Toviaz® prolonged-release tablets
             contain lactose)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hankook General Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>360-090</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Urology Clinic</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>361-814</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Urology Clinic</name>
      <address>
        <city>Yeongdong-gun</city>
        <state>Chungcheongbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soo Urology Clinic</name>
      <address>
        <city>Asan-si</city>
        <state>Chungcheongnam-do</state>
        <zip>336-010</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seo Kyung-Keun Urology Clinic</name>
      <address>
        <city>Cheonan-si</city>
        <state>Chungcheongnam-do</state>
        <zip>330-730</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheonan Medical Center</name>
      <address>
        <city>Cheonan-Si</city>
        <state>Chungcheongnam-do</state>
        <zip>330-930</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Song In-Ho Urology Clinic</name>
      <address>
        <city>Dangjin-si</city>
        <state>Chungcheongnam-Do</state>
        <zip>343-920</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Urology Clinic</name>
      <address>
        <city>Gongju-si</city>
        <state>Chungcheongnam-do</state>
        <zip>314-030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Urology Clinic</name>
      <address>
        <city>Gongju-si</city>
        <state>Chungcheongnam-Do</state>
        <zip>314-050</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moa gynecology</name>
      <address>
        <city>Nonsan-si</city>
        <state>Chungcheongnam-do</state>
        <zip>320-803</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jung Woong Gyo Urology Clinic</name>
      <address>
        <city>Wonju-si</city>
        <state>Gangwon-do</state>
        <zip>220-903</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim Tae Joon Internal Medicine</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-Do</state>
        <zip>425-778</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ansan Themapark Medical Center</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-Do</state>
        <zip>425-020</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woosung Yusung Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-Do</state>
        <zip>425-868</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoo And Lee Dematology Urology Clinic</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-Do</state>
        <zip>420-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Myung Urology Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-Do</state>
        <zip>420-849</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gimpo Woori Hospital</name>
      <address>
        <city>Gimpsi</city>
        <state>Gyeonggi-do</state>
        <zip>415-020</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Clinic</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-Do</state>
        <zip>410-350</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hwang Family Medicine Clinic</name>
      <address>
        <city>Goyang-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>411-848</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Urology Clinic</name>
      <address>
        <city>Namyangju-si</city>
        <state>Gyeonggi-do</state>
        <zip>472-900</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Dermatology And Urology Clinic</name>
      <address>
        <city>Pyeongtaek</city>
        <state>Gyeonggi-Do</state>
        <zip>450-828</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good morning Clinic, Pyeongtaek</name>
      <address>
        <city>Pyeongtaek</city>
        <state>Gyeonggi-do</state>
        <zip>450-833</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheong Urology Clinic</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>461-825</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Seung Soo Urology Clinic</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-Do</state>
        <zip>462-817</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Urology Clinic</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>462-835</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bes Top Urology Clinic</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-805</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Urology Clinic</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-Do</state>
        <zip>463-050</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongsuwon General Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>442-816</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim Dae Sung Clinic</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeonggi-Do</state>
        <zip>480-800</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johan Urology Clinic</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeonggi-do</state>
        <zip>480-848</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Min Urology Clinic</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeonggi-Do</state>
        <zip>480-867</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choi Won Suk urology clinic</name>
      <address>
        <city>Yongin-si</city>
        <state>Gyeonggi-do</state>
        <zip>448-509</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haram Urology Clinic</name>
      <address>
        <city>Yongin-si</city>
        <state>Gyeonggi-Do</state>
        <zip>449-924</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Urology Clinic</name>
      <address>
        <city>Yongin</city>
        <state>Gyeonggi-Do</state>
        <zip>446-597</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Duck Young Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <zip>300-160</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeonhap Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <zip>301-827</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taepyung urology clinic</name>
      <address>
        <city>Daejeon</city>
        <zip>301-845</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ssen Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <zip>302-831</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Duck Young Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim Se Gyeom Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwon Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeonhap Urology Clinic</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incheon Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>401-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incheonsarang Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>402-201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Urology Clinic</name>
      <address>
        <city>Incheon</city>
        <zip>403-733</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanvit Urology Clinic</name>
      <address>
        <city>Incheon</city>
        <zip>407-824</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee and Lee dermatology urology clinic</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songdo Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Cho &amp; Lee's Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>100-845</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Won Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>110-061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lim Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>121-806</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-811</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woo Tae Hyung urology clinic</name>
      <address>
        <city>Seoul</city>
        <zip>130-846</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S-Up Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>132-898</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Yong Hyun Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>133-867</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saerom urology clinic</name>
      <address>
        <city>Seoul</city>
        <zip>134-840</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Kyu Hong Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>134-874</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seonreung Top Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>135-922</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Woono Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>135-931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daehang Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-820</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Byung Dae Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>137-887</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jin Kilnam Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>137-909</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bes Top Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>138-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Song Woung Soeg Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>138-846</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim Jun-Ho Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>138-854</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hong Don Ho Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>138-862</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boram St.Mary's Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>139-820</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nowon Paik Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>139-838</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Su clinic</name>
      <address>
        <city>Seoul</city>
        <zip>139-838</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uh's Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>139-942</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Top Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>142-874</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urotop Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>142-878</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoo Jong Keun Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>142-878</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lim Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>143-716</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seong Ae Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>150-960</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Ace Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>151-892</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woo ri dermatology urology clinic</name>
      <address>
        <city>Seoul</city>
        <zip>153-841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bae Urology Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>153-858</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jung Ho Hyun Urology Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>156-832</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miz-Medi Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>157-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choi Urology Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>157-807</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan Jeil Hopital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221075&amp;StudyName=Toviaz%20Post%20Marketing%20Surveillance%20Study</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <results_first_submitted>August 6, 2015</results_first_submitted>
  <results_first_submitted_qc>August 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2015</results_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between November 2009 and August 2014 from 235 Korean medical care centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Toviaz</title>
          <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2434"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="675"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Visit Stop</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: regardless of treatment period, all participants who received study drug once or more, including dropouts due to adverse event (AE), were included in the safety analysis set. Participants who started Toviaz prior to the contract date or violated usage of maximum daily dose of 8 mg were excluded from the safety analysis set.</population>
      <group_list>
        <group group_id="B1">
          <title>Toviaz</title>
          <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.22" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An AE was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event was not necessarily had a causal relationship with the treatment or usage. All AEs reported after start of administration of Toviaz were considered as TEAEs.</description>
        <time_frame>From the time that the participant signed data privacy statement through and including 28 calendar days after the last administration of the study drug.</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An AE was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event was not necessarily had a causal relationship with the treatment or usage. All AEs reported after start of administration of Toviaz were considered as TEAEs.</description>
          <population>Safety Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator's Final Assessment of Effectiveness at the End of Study Treatment</title>
        <description>The final efficacy assessment included improvement, no change, aggravation, and unevaluable evaluated by the investigator based on the subject's symptoms of frequent micturition, urgency, and urgency urinary incontinence (UUI).</description>
        <time_frame>At the end of study treatment</time_frame>
        <population>Per-Protocol (PP) Population: participants who had evaluable data and were eligible for the efficacy assessment of the approved indication. The method of last observation carried forward was used in the analysis of effectiveness endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Final Assessment of Effectiveness at the End of Study Treatment</title>
          <description>The final efficacy assessment included improvement, no change, aggravation, and unevaluable evaluated by the investigator based on the subject's symptoms of frequent micturition, urgency, and urgency urinary incontinence (UUI).</description>
          <population>Per-Protocol (PP) Population: participants who had evaluable data and were eligible for the efficacy assessment of the approved indication. The method of last observation carried forward was used in the analysis of effectiveness endpoints.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2978"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Micturitions Per 24 Hours at the End of Study Treatment</title>
        <description>The number of micturitions per 24 hours was recorded in the case report form (CRF) by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
        <time_frame>Baseline and at the end of study treatment</time_frame>
        <population>PP Population; n refers to the number of participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Micturitions Per 24 Hours at the End of Study Treatment</title>
          <description>The number of micturitions per 24 hours was recorded in the case report form (CRF) by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
          <population>PP Population; n refers to the number of participants with evaluable data.</population>
          <units>Number of Episodes per 24 Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2718)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.05" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study Treatment (n=2718)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (n=2718)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Urgency Episodes Per 24 Hours at the End of Study Treatment</title>
        <description>The number of urgency episodes per 24 hours was recorded in the CRF by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
        <time_frame>Baseline and at the end of study treatment</time_frame>
        <population>PP Population; n refers to the number of participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Urgency Episodes Per 24 Hours at the End of Study Treatment</title>
          <description>The number of urgency episodes per 24 hours was recorded in the CRF by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
          <population>PP Population; n refers to the number of participants with evaluable data.</population>
          <units>Number of Episodes per 24 Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2724"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2724)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study Treatment (n=2724)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (n=2724)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of UUI Episodes Per 24 Hours at the End of Study Treatment</title>
        <description>The number of UUI episodes per 24 hours was recorded in the CRF by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
        <time_frame>Baseline and at the end of study treatment</time_frame>
        <population>PP Population; n refers to the number of participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of UUI Episodes Per 24 Hours at the End of Study Treatment</title>
          <description>The number of UUI episodes per 24 hours was recorded in the CRF by the investigator. Baseline was defined as data collected within 1 week prior to the first visit.</description>
          <population>PP Population; n refers to the number of participants with evaluable data.</population>
          <units>Number of Episodes per 24 Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2800)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of study treatment (n=2800)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline (n=2800)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Perception of Bladder Condition at the End of Study Treatment</title>
        <description>Participant perception of bladder condition was recorded in the CRF by the investigator. Participants were asked at baseline (BL) and at the end of study treatment (EOT) if the extent to which their bladder condition caused them problems. The possible responses were: No Problem, Very Minor Problems, Minor Problems, Moderate Problems, Severe Problems, or Many Severe Problems.</description>
        <time_frame>Baseline and at the end of study treatment</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Perception of Bladder Condition at the End of Study Treatment</title>
          <description>Participant perception of bladder condition was recorded in the CRF by the investigator. Participants were asked at baseline (BL) and at the end of study treatment (EOT) if the extent to which their bladder condition caused them problems. The possible responses were: No Problem, Very Minor Problems, Minor Problems, Moderate Problems, Severe Problems, or Many Severe Problems.</description>
          <population>PP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL: No Problem/EOT: No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: No Problem/EOT: Very Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: No Problem/EOT: Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: No Problem/EOT: Moderate Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: No Problem/EOT: Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: No Problem/EOT: Many Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Very Minor Problems/EOT:No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL:Very Minor Problems/EOT: Very Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Very Minor Problems/EOT: Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Very Minor Problems/EOT: Moderate Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Very Minor Problems/EOT: Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Very Minor Problems/EOT: Many Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Minor Problems/EOT: No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Minor Problems/EOT: Very Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Minor Problems/EOT: Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Minor Problems/EOT:Moderate Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Minor Problems/EOT: Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Minor Problems/EOT: Many Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate Problems/EOT: No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate Problems/EOT: Very Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate Problems/EOT: Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate Problems/EOT: Moderate Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate Problems/EOT: Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate Problems/EOT: Many Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe Problems/EOT: No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe Problems/EOT: Very Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe Problems/EOT: Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe Problems/EOT: Moderate Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe Problems/EOT: Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe Problems/EOT: Many Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Many Severe Problems/EOT: No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Many Severe Problems/EOT: Very Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Many Severe Problems/EOT: Minor Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Many Severe Problems/EOT: Moderate Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Many Severe Problems/EOT: Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Many Severe Problems/EOT: Many Severe Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Final Efficacy Assessment of Effective by Baseline and Treatment Characteristics</title>
        <description>Participants who were assessed as having improved from their baseline condition in the final efficacy assessment were considered as “effective”. Baseline and treatment characteristics included: geriatric status (&lt;65 years or ≥65 years), age categories, gender, weight categories, height categories, allergic history, duration of disease, past overactive bladder (OAB) treatment history, medical history, kidney and liver disorders, concomitant medication, total administration period of Toviaz, completion status, daily dose of Toviaz, and long term administration of Toviaz (&lt;274 days and ≥274 days) .</description>
        <time_frame>At the end of study treatment</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Toviaz</title>
            <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Final Efficacy Assessment of Effective by Baseline and Treatment Characteristics</title>
          <description>Participants who were assessed as having improved from their baseline condition in the final efficacy assessment were considered as “effective”. Baseline and treatment characteristics included: geriatric status (&lt;65 years or ≥65 years), age categories, gender, weight categories, height categories, allergic history, duration of disease, past overactive bladder (OAB) treatment history, medical history, kidney and liver disorders, concomitant medication, total administration period of Toviaz, completion status, daily dose of Toviaz, and long term administration of Toviaz (&lt;274 days and ≥274 days) .</description>
          <population>PP Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2978"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.13" lower_limit="89.06" upper_limit="90.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Geriatric Status: &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.86" lower_limit="89.47" upper_limit="90.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Geriatric Status: ≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.20" lower_limit="87.52" upper_limit="89.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category: &lt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.27" lower_limit="89.07" upper_limit="91.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category: 50 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.08" lower_limit="88.87" upper_limit="91.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category: 60 to 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.29" lower_limit="87.22" upper_limit="89.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category: 70 to 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.45" lower_limit="87.13" upper_limit="89.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category: ≥80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.27" lower_limit="84.71" upper_limit="89.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.98" lower_limit="87.41" upper_limit="89.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.36" lower_limit="89.91" upper_limit="91.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Category: &lt;50 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.73" lower_limit="85.36" upper_limit="90.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Category: 50 to &lt;60 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.64" lower_limit="89.72" upper_limit="91.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Category: 60 to &lt;70 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.32" lower_limit="88.47" upper_limit="90.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Category: ≥70 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.82" lower_limit="86.59" upper_limit="88.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Height Category: &lt;160 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.99" lower_limit="87.93" upper_limit="90.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Height Category: 160 to 170 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.32" lower_limit="88.57" upper_limit="90.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Height Category: ≥170 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.35" lower_limit="88.33" upper_limit="90.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic History: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.22" lower_limit="71.05" upper_limit="83.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic History: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.25" lower_limit="89.18" upper_limit="90.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: &lt;1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.40" lower_limit="91.18" upper_limit="92.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: 1 to &lt;8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.42" lower_limit="85.90" upper_limit="89.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: 8 to &lt;16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.05" lower_limit="83.82" upper_limit="89.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: ≥16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.33" lower_limit="81.54" upper_limit="84.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past OAB Treatment History: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.30" lower_limit="82.79" upper_limit="85.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past OAB Treatment History: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.79" lower_limit="90.64" upper_limit="91.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Existence for Medical History of Past Disease: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.96" lower_limit="84.80" upper_limit="88.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Existence for Medical History of Past Disease: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.47" lower_limit="89.34" upper_limit="90.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical History of Present Disease: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.96" lower_limit="86.34" upper_limit="88.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical History of Present Disease: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.46" lower_limit="91.10" upper_limit="92.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Disease: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.00" lower_limit="71.41" upper_limit="95.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Disease: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.13" lower_limit="89.05" upper_limit="90.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disorder: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.31" lower_limit="77.82" upper_limit="96.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disorder: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.12" lower_limit="89.04" upper_limit="90.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administration Period of Toviaz: &lt;2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.22" lower_limit="82.96" upper_limit="85.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administration Period of Toviaz: 2 to &lt;4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.44" lower_limit="91.16" upper_limit="92.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administration Period Of Toviaz: ≥ 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.33" lower_limit="89.64" upper_limit="92.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Dose of Toviaz: 3 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="13.32" upper_limit="97.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Dose of Toviaz: 4 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.65" lower_limit="89.51" upper_limit="90.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Dose of Toviaz: &gt;4 to &lt;8 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.25" lower_limit="80.80" upper_limit="85.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Dose of Toviaz: 8 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.25" lower_limit="86.47" upper_limit="90.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.28" lower_limit="91.22" upper_limit="92.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.72" lower_limit="77.44" upper_limit="80.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Administration Period &lt;274 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.16" lower_limit="89.09" upper_limit="90.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Administration Period ≥274 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" lower_limit="77.25" upper_limit="89.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Existence for Concurrent Medication: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.48" lower_limit="86.92" upper_limit="88.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Existence for Concurrent Medication: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.08" lower_limit="90.65" upper_limit="92.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geriatric Status: &lt;65 years versus (vs) Geriatric Status: ≥65 years</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1319</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Age Categories: &lt;50 years, 50 to 59 years, 60 to 69 years, 70 to 79 years, and ≥80 years.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6010</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Male vs Female</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0289</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Weight Categories: &lt;50 kg, 50 to 60 kg, 60 to 70 kg, and ≥70 kg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3078</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Height Categories: &lt;160 cm, 160 to 170 cm, and ≥170 cm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9614</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Allergic History: Yes vs Allergic History: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0788</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Duration of Disease: &lt;1 week, 1 to 8 weeks, 8 to 16 weeks, and ≥16 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Past OAB Treatment History: Yes vs Past OAB Treatment History: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Medical History of Past Disease: Yes vs Medical History of Past Disease: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1147</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Medical History of Present Disease: Yes vs Medical History of Present Disease: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Kidney Disorder: Yes vs Kidney Disorder: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Liver Disorder: Yes vs Liver Disorder: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Total Administration Period of Toviaz Subgroups: &lt;2 months, 2 to 4 months, and ≥4 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Daily Dose of Toviaz: 3 mg, 4 mg, &gt;4 mg to &lt;8 mg, and 8 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0239</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Completion vs Discontinuation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Total Administration Period &lt;274 days vs Total Administration Period ≥ 274 days</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5889</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Concurrent Medication: Yes vs Concurrent Medication: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time that the participant signed data privacy statement through and including 28 calendar days after the last administration of the study drug.</time_frame>
      <desc>The same event may appear as both an AE and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Toviaz</title>
          <description>Participants were administered with Toviaz as part of routine care. The use and dosage recommendations for Toviaz were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>WHO-ART version 092</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="3107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="3107"/>
              </event>
              <event>
                <sub_title>Mouth dry</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="3107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="3107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

